ANGIODYNAMICS INC

Listed Company

ANGOCIK 0001275187NasdaqAcceleratedSurgical & Medical Instruments & ApparatusDelawareFY ends May 31

Period

FY 2026

Revenue

$320.17M

Net Income

$-36.74M

Total Assets

$267.16M

Equity

$170.82M

Shares Out

41.33M

Op. Cash Flow

$3.09M

ANGO$13.49+54.17% · past yearDBEQ Basic

Daily closing prices

Business

AngioDynamics is a medical technology company that designs, manufactures and sells products and technologies for treating patients with cardiovascular disease and cancer. The company offers ablation systems (Auryon, NanoKnife, Solero microwave), thrombus management devices (AlphaVac, AngioVac, Uni-Fuse), peripheral intervention products (angiographic catheters, guidewires, drainage catheters), vascular access ports and venous insufficiency treatments (VenaCure EVLT laser). AngioDynamics operates through two reportable segments—Med Tech and Med Device—and sells primarily in the United States through a direct sales force and internationally through direct sales and distributors.

Summary from 10-K filed 2026-07-14

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	May 31, 2026 2026-05-31	May 31, 2025 2025-05-31	May 31, 2024 2024-05-31
Net sales	320	292	304
Cost of sales (exclusive of intangible amortization)	145	135	149
Gross margin	175	158	155
Operating expenses	—	—	—
Research and development	29	26	32
Sales and marketing	113	103	103
General and administrative	44	42	41
Amortization of intangibles	11	10	13
Goodwill impairment	0	0	159
Change in fair value of contingent consideration	0	272,000	432,000
Acquisition, restructuring and other items, net	18	16	53
Total operating expenses	215	198	402
Gain on sale of assets	0	0	54
Operating loss	−40	−40	−192
Other expenses	—	—	—
Interest income (expense), net	−299,000	978,000	2
Other income (expense), net	4	5	−817,000
Total other income, net	4	6	797,000
Loss before income tax expense (benefit)	−36	−34	−192
Income tax expense (benefit)	442,000	−39,000	−7
Net loss	−37	−34	−184
Loss per share	—	—	—
Basic (usd per share)	−0.88	−0.83	−4.59
Diluted (usd per share)	−0.88	−0.83	−4.59
Weighted average shares outstanding	—	—	—
Basic (in shares)	42	41	40
Diluted (in shares)	42	41	40

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	May 31, 2026 2026-05-31	May 31, 2025 2025-05-31
Assets	—	—
Current Assets	—	—
Cash and cash equivalents	54	56
Accounts receivable, net of allowances of $1,851 and $2,215 respectively	48	43
Inventories	52	62
Prepaid expenses and other	9	8
Total current assets	163	168
Property, plant and equipment, Net	27	32
Intangible assets, net	67	69
Other assets	9	10
Total Assets	267	280
Liabilities and Stockholders' Equity	—	—
Current Liabilities	—	—
Accounts payable	32	33
Accrued liabilities	39	36
Other current liabilities	4	7
Total current liabilities	75	76
Deferred income taxes	5	4
Other long-term liabilities	16	17
Total Liabilities	96	97
Commitments and Contingencies (Note 17)	—	—
Stockholders’ Equity	—	—
Preferred stock, par value $0.01 per share, 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, par value $0.01 per share, 75,000,000 shares authorized; 42,314,266 and 41,607,877 shares issued and 41,700,419 and 40,994,030 shares outstanding at May 31, 2026 and 2025, respectively	387,000	385,000
Additional paid-in capital	636	621
Accumulated deficit	−466	−429
Treasury stock, 613,847 shares, at cost at May 31, 2026 and 2025, respectively	7	7
Accumulated other comprehensive loss	8	−2
Total Stockholders' Equity	171	183
Total Liabilities and Stockholders' Equity	267	280
Treasury stock, shares (shares)	613,847	613,847

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	May 31, 2026 2026-05-31	May 31, 2025 2025-05-31	May 31, 2024 2024-05-31
Cash flows from operating activities:	—	—	—
Net loss	−37	−34	−184
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:	—	—	—
Depreciation and amortization	23	26	28
Non-cash lease expense	2	2	2
Non-cash interest expense	290,000	0	0
Goodwill impairment	0	0	159
Stock based compensation	14	10	11
Gain on dispositions	0	0	54
Transaction costs for disposition	0	0	−5
Change in fair value of contingent consideration	0	272,000	432,000
Deferred income tax provision	143,000	−988,000	−8
Changes in accounts receivable allowances	313,000	699,000	1
Asset impairments and disposals	1	173,000	7
Write-off of other assets	0	0	869,000
Other	−2	−291,000	62,000
Changes in operating assets and liabilities:	—	—	—
Accounts receivable	6	−23,000	−8
Inventories	−10	1	9
Prepaid expenses and other	1	−3	12
Accounts payable, accrued and other liabilities	−6	−16	28
Net cash provided by (used in) operating activities	3	−10	−28
Cash flows from investing activities:	—	—	—
Additions to property, plant and equipment	3	4	3
Additions to placement and evaluation units	3	6	5
Proceeds from sale of assets	0	0	135
Acquisition of intangibles	0	0	3
Net cash (used in) provided by investing activities	−6	−10	124
Cash flows from financing activities:	—	—	—
Repayment of long-term debt	0	0	50
Deferred financing costs on long-term debt	0	680,000	0
Principal payments on financing arrangement	375,000	148,000	0
Proceeds from financing arrangement	0	6	0
Payment of acquisition related contingent consideration	0	5	15
Repurchase of common stock	0	2	0
Proceeds from exercise of stock options and employee stock purchase plan	939,000	933,000	752,000
Net cash provided by (used in) financing activities	564,000	−255,000	−64
Effect of exchange rate changes on cash and cash equivalents	267,000	398,000	125,000
Increase (decrease) in cash and cash equivalents	−2	−20	31
Cash and cash equivalents at beginning of year	56	76	45
Cash and cash equivalents at end of year	54	56	76
Supplemental disclosure of non-cash investing and financing activities:	—	—	—
Increase (decrease) in accounts payable for purchases of fixed assets	−68,000	−49,000	−78,000
Cash paid during the year for:	—	—	—
Interest	426,000	185,000	0
Income taxes	405,000	800,000	455,000

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is ANGIODYNAMICS INC's CIK number?

ANGIODYNAMICS INC's SEC CIK number is 0001275187 (1275187). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find ANGIODYNAMICS INC's SEC filings?

All of ANGIODYNAMICS INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did ANGIODYNAMICS INC last report earnings?

ANGIODYNAMICS INC (ANGO) most recently filed an earnings 8-K with the SEC on Jul 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001140361-26-028368). This is ANGIODYNAMICS INC's most recent earnings filing of record — not a forecast of its next earnings date.

What is ANGIODYNAMICS INC's most recent earnings 8-K?

ANGIODYNAMICS INC's latest earnings 8-K (Item 2.02) was filed Jul 14, 2026 under accession 0001140361-26-028368. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View ANGIODYNAMICS INC's latest earnings 8-K →
Look up any company's CIK number →